Scientific article
English

Long-term control with etanercept (Enbrel) of a severe acrodermatitis continua of Hallopeau refractory to infliximab (Remicade)

Published inDermatology, vol. 217, no. 2, p. 137-139
Publication date2008
Abstract

Hallopeau's acrodermatitis is characterized by the presence of aseptic pustules on an inflammatory basis of the periungual or subungual region. The cyclic recurrences induce important physical and psychological morbidity. By analogy to the efficacy of TNF-alpha antagonists in the treatment of generalized pustular psoriasis, our patient illustrates the long-term efficacy and safety of etanercept (Enbrel) in the treatment of Hallopeau's acrodermatitis refractory to infliximab (Remicade). This treatment alternative should in consequence be considered in patients with a recalcitrant form of a potentially debilitating disease.

Keywords
  • Acrodermatitis/diagnosis/drug therapy
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Follow-Up Studies
  • Hand Dermatoses/diagnosis/drug therapy
  • Humans
  • Immunoglobulin G/therapeutic use
  • Male
  • Middle Aged
  • Receptors, Tumor Necrosis Factor/therapeutic use
  • Risk Assessment
  • Severity of Illness Index
  • Time Factors
  • Treatment Outcome
  • Tumor Necrosis Factor-alpha/antagonists & inhibitors/therapeutic use
Citation (ISO format)
THIELEN, A-M. et al. Long-term control with etanercept (Enbrel) of a severe acrodermatitis continua of Hallopeau refractory to infliximab (Remicade). In: Dermatology, 2008, vol. 217, n° 2, p. 137–139. doi: 10.1159/000134613
Main files (1)
Article (Accepted version)
accessLevelRestricted
Identifiers
Journal ISSN1018-8665
657views
0downloads

Technical informations

Creation11/03/2009 09:18:00
First validation11/03/2009 09:18:00
Update14/03/2023 15:03:14
Status update14/03/2023 15:03:14
Last indexation29/10/2024 11:20:01
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack